IGI Logo

Alembic Pharmaceuticals is currently trading at Rs. 959.35, up by 16.85 points or 1.79% from its previous closing of Rs. 942.50 on the BSE.

The scrip opened at Rs. 942.50 and has touched a high and low of Rs. 960.00 and Rs. 936.70 respectively. So far 3793 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1093.05 on 21-Feb-2024 and a 52 week low of Rs. 542.40 on 31-May-2023.

Last one week high and low of the scrip stood at Rs. 974.90 and Rs. 926.00 respectively. The current market cap of the company is Rs. 18673.50 crore.

The promoters holding in the company stood at 69.61%, while Institutions and Non-Institutions held 19.84% and 10.54% respectively.

Alembic Pharmaceuticals (Alembic) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Sacubitril and Valsartan Tablets, 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Entresto Tablets, 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, of Novartis Pharmaceuticals Corporation (Novartis). 

Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. It is also indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in paediatric patients aged one year and older. Sacubitril and Valsartan Tablets have an estimated market size of $5.3 billion for twelve months ending March 2024 according to IQVIA. Alembic has a cumulative total of 202 ANDA approvals (174 final approvals and 28 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.